The first weekly long-acting hemophilia therapy has been approved by the FDA from Pfizer
芊芊551
发表于 2024-10-12 11:20:13
142
0
0
On October 11th local time, the US FDA approved Pfizer's drug Hympavzi (marstalimab) for routine prevention or reduction of bleeding in adult and pediatric patients aged 12 and above with hemophilia A and hemophilia B, who do not contain inhibitors of coagulation factors VIII and IX (neutralizing antibodies).
It is reported that this therapy is the first hemophilia B therapy that only requires subcutaneous injection once a week. It can be used to treat hemophilia A and hemophilia B patients by targeting tissue factor pathway inhibitors (TFPI).
This innovative therapy has been granted fast track status by the US FDA. In phase 2 clinical trials, it was able to reduce the annual bleeding rate of participants by over 75%.
It is worth mentioning that this innovative therapy for hemophilia has also been approved for clinical trials in China.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Pfizer fights cancer business again, plans to expand these territories in China within six years
- Pfizer's Q2 2024 revenue of $13.3 billion
- Pfizer's new hemophilia treatment drug Mataximab's application for market launch in China has been accepted
- The number of infected cases has surged! US FDA approves Pfizer and Modena's updated COVID-19 vaccine
- Pfizer launches drug sales platform directly targeting American patients
- The Phase II clinical trial of Pfizer Ponsegromab in the treatment of cancer cachexia has reached its primary endpoint
- Pfizer and Shangyao Holdings have reached a strategic cooperation to jointly create a new format of high-quality preventive immunization services
- Pfizer CEO may meet with key executives of radical investor Starboard Value next week
- Pfizer Beijing R&D Center settles in BioPark, Beijing Medical Innovation Park
-
バークレイズはテスラの目標価格を220ドルから235ドルに引き上げた。
- hecgdge4
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
「極クリプトンMIXの開発投入は、中大型SUVの2.8倍である」最近、吉利控股集団総裁で極クリプトン知能科学技術CEOの安聡慧氏は第一財経記者の取材に対し、MIXは予定通り納品され、吉利が30年近く車を作ってきた中で ...
- 寒郁轩良
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
10月30日、ソニーによると、ソニーは2024中国国際輸入博覧会に参加し、技術装備展示エリア3 A 2-04に登場する。 ソニーによると、同社は「技術によるクリエイティブと持続可能性」をテーマに、クリエイティブと持続 ...
- 就放荡不羁就h
- 前天 18:06
- 支持
- 反对
- 回复
- 收藏
-
スポーツ競技場では、選手の競争が激しく、競技場の外では、各スポーツブランドの販売競争も同様に焦眉している。 世界的なスポーツ用品大手ナイキがこのほど発表した最新の業績は、利益が共に減少していることを示 ...
- 刘moon
- 昨天 17:23
- 支持
- 反对
- 回复
- 收藏